Fepixnebart

DB19079InvestigationalProtein Based Therapies

Fepixnebart is under investigation in clinical trial NCT04456686 (Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis).

Mechanism: Pharmacologically active on Protransforming growth factor alpha and Proepiregulin
Curator reviewed
Also known as: IMMUNOGLOBULIN G4 (226-PROLINE,232-ALANINE,233-ALANINE,DE-C-TERMINAL-LYSINE), ANTI-(HUMAN EPIREGULIN AND TRANSFORMING GROWTH FACTOR .ALPHA.) (HUMAN-MUS MUSCULUS MONOCLONAL LY3016859 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL LY3016859 · Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin)
Code names: LY-3016859

Resolves to

Compound

UNIIFP2PL0HRK8CAS1799706-87-8

Targets

P01135TGFAO14944EREG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fepixnebart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account